← Back to all signals
RESEARCH PAPER ANALYSIS

What Are the Complications, Reconstruction Survival, and Functional Outcomes of Modular Prosthesis and Allograft-prosthesis Composite for Proximal Femur Reconstruction in Children With Primary Bone Tumors?

AI interpretation is pending for this paper.

Open original publication →
PMID39235267
JournalClinical orthopaedics and related research
Publication Date2024-09-03
Ingested2026-08-02 12:02 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: Proximal femur reconstruction after bone tumor resection in children is a demanding surgery for orthopaedic oncologists because of the small bone size and possible limb-length discrepancy at the end of skeletal growth owing to physis loss. The most commonly used reconstruction types used for the proximal femur are modular prostheses and allograft-prosthesis composites. To our knowledge, there are no previous studies comparing the outcomes after modular prosthesis and allograft-prosthesis composite reconstruction of the proximal femur in children with primary bone tumors. QUESTIONS/PURPOSES: (1) What was the cumulative incidence of reoperation for any reason after allograft-prosthesis composite and modular prosthesis reconstructions of the proximal femur in children with primary bone tumors? (2) What was the cumulative incidence of reconstruction removal or revision arthroplasty in those two treatment groups? (3) What complications occurred in those two treatment groups that were managed without further surgery or with surgery without reconstruction removal? METHODS: Between 2000 and 2021, 54 children with primary bone tumors underwent resection and reconstruction of the proximal femur at a single institution. During that time, allograft-prosthesis composite reconstruction was used in very young children, in whom we prioritize bone stock preservation for future surgeries, and children with good response to chemotherapy, while modular prosthesis reconstruction was used in older children and children with metastatic disease at presentation and poor response to chemotherapy. We excluded three children in whom limb salvage was not possible and 11 children who underwent either reconstruction with free vascularized fibular graft and massive bone allograft (n = 3), an expandable prosthesis (n = 3), a massive bone allograft reconstruction (n = 2), a rotationplasty (n = 1), standard (nonmodular) prosthesis (n = 1), or revision of preexisting reconstruction (n = 1). Further, we excluded two children who were not treated surgically, three children with no medical or imaging records, and three children with no follow-up. All the remaining 32 children with reconstruction of the proximal femur (12 children treated with modular prosthesis and 20 children treated with allograft-prosthesis composite reconstruction) were accounted for at a minimum follow-up time of 2 years. Children in the allograft-prosthesis group were younger at the time of diagnosis than those in the modular prosthesis group (median 8 years [range 1 to 16 years] versus 15 years [range 9 to 17 years]; p = 0.001]), and the follow-up in the allograft-prosthesis composite group was longer (median 5 years [range 1 to 23 years] versus 3 years [range 1 to 15 years]; p = 0.37). Reconstruction with hemiarthroplasty was performed in 19 of 20 children in the allograft-prosthesis composite group and in 9 of 12 children in the modular prosthesis group. A bipolar head was used in 16 of 19 children, and a femoral ceramic head without acetabular cup was used in 3 of 19 children in the allograft-prosthesis composite reconstruction group. All 9 children in the modular prosthesis group were reconstructed with a bipolar hemiarthroplasty. Reconstruction with total arthroplasty was performed in one child in the allograft-prosthesis composite group and in three children in the modular prosthesis group. For both groups, we calculated the cumulative incidence of reoperation for any reason and the cumulative incidence of reconstruction removal or revision arthroplasty; we also reported qualitative descriptions of serious complications treated nonoperatively in both groups. RESULTS: The cumulative incidence of any reoperation at 10 years did not differ between the groups with the numbers available (36% [95% confidence interval 15% to 58%] in the allograft-prosthesis composite group versus 28% [95% CI 5% to 58%] in the modular proximal femoral replacement group). The cumulative incidence of reconstruction removal or revision arthroplasty at 10 years likewise did not differ between the groups with the numbers available (10% [95% CI 2% to 28%] versus 12% [95% CI 0% to 45%], respectively). In the allograft-prosthesis composite group (20 children), hip instability (n = 3), nonunion (n = 2), fracture of the greater trochanter (n = 1), screw loosening (n = 1), limb-length discrepancy (n = 1), and coxalgia due to acetabular wear (n = 1) were treated surgically without reconstruction removal. Complications treated without surgery included resorption of the allograft at the trochanteric region (n = 4), fracture of the greater trochanter (n = 4), limb-length discrepancy (n = 6), and coxalgia due to acetabular wear (n = 2). In the modular prosthesis group (12 children), hip instability (n = 1), coxalgia due to acetabular wear (n = 1), and limb-length discrepancy (n = 1) were treated surgically without reconstruction removal. Complications treated without surgery included hip instability (n = 2), stress shielding (n = 6), infection (n = 1), sciatic nerve palsy (n = 1), and limb-length discrepancy (n = 3). CONCLUSION: Although the two groups of children were not directly comparable due to differences in age and clinical characteristics, both modular prosthesis and allograft-prosthesis composite reconstructions of the proximal femur after bone tumor resection appear to be reasonable options with similar revision-free survival and complications. Therefore, the type of reconstruction following proximal resection in children with bone sarcoma should be chosen taking into consideration factors such as patient age, bone size, implant availability, technical expertise, and the surgeon's preference. Although children treated with expandable prostheses were not included in this study, such prostheses may be useful in bridging the surgical defect while correcting residual limb-length discrepancies even though they face limitations such as small intramedullary diameter, short residual bone segments, as well as stress shielding, loosening, and breakage. LEVEL OF EVIDENCE: Level III, therapeutic study.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 Comparison of Phenol Application and Endoscopic Pilonidal Sinus Treatment in Pediatric Pilonidal Sinus Disease. Pediatrics international : official journal of the Japan Pediatric Society 63.74 2 Unfinished Business and Experiences of Bereaved Families of Patients with Cancer: A Cross-Sectional Survey. Palliative medicine reports 61.0 3 The 21st International ``Ponte di Legno'' Childhood Acute Lymphoblastic Leukemia Workshop Report: Progress and Emerging Opportunities. Clinical lymphoma, myeloma & leukemia 49.0 4 Acute Leukemia During the First Six Months of Life: A Population-Based Analysis of Survival by Leukemia Type. Clinical lymphoma, myeloma & leukemia 64.12 5 Pediatric orbital solitary fibrous tumor/hemangiopericytoma presenting with isolated eyelid edema: a case report. Frontiers in pediatrics 53.1 6 Malignancies in patients with inborn errors of immunity: insights from 20-years of clinical experience in Qatar. Frontiers in immunology 68.6 7 Precision medicine and parental experience: a longitudinal study of psychosocial responses to germline genomic results in pediatric oncology. Frontiers in medicine 67.36 8 Cytokine-augmented risk stratification for six-month incident nephritis in children with IgA vasculitis. Frontiers in pediatrics 58.5 9 Time-bounded uncertainty in childhood cancer survivorship: a psycho-oncology perspective on result communication. Frontiers in psychology 57.0 10 "From misdiagnosis to precision medicine: strengthening pediatric neuro-oncology care in LMICs toward equitable pLGG outcomes". Frontiers in oncology 75.5 11 Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper. European journal of neurology 66.4 12 Technical Considerations for Robotic Pediatric Lobectomy. Annals of thoracic surgery short reports 54.0 13 Kaposi Sarcoma-Associated Herpesvirus Is Not Detected in Osteosarcoma From KSHV-Endemic African Countries and the Non-Endemic United States Populations. Journal of medical virology 59.5 14 ELISA (Embedding-Linked Interactive Single-cell Agent): an interpretable hybrid generative Artificial Intelligence agent for expression-grounded discovery in single-cell genomics. Briefings in bioinformatics 48.5 15 Thyroid Cancer in the Modern Era: From Molecular Landscape and Multimodal Diagnostics to Integrative Traditional Chinese Medicine-A Comprehensive Review. Cancer management and research 90.6 16 Presumed left atrial myxoma presenting with seizures, massive stroke, and systemic embolization in an adolescent: a case report. International journal of emergency medicine 49.0 17 Ewing's Sarcoma in Adults: A Predictive Nomogram and Survival Analysis of a Cohort of 937 Patients. Journal of surgical oncology 73.92 18 Comments on "Initial Cerebrospinal Fluid Blast Clearance Rate in Pediatric B-Lymphoblastic Leukemia Is Associated With Overall Survival". Journal of pediatric hematology/oncology 49.12 19 Impact of Number of Lymph Nodes Sampled and Density of Positive Nodes on Outcomes Among Over 2000 Patients With Stage I to III Favorable Histology Wilms Tumor Enrolled on AREN03B2: A Children's Oncology Group Renal Tumor Study. Annals of surgery 70.5 20 Prognostic impact of risk organ involvement and metabolic parameters assessed by staging 18F-FDG PET/CT in pediatric Langerhans cell histiocytosis. Nuclear medicine communications 63.3 21 Prognostic value of plasma thymus- and activationregulated chemokine levels after the second cycle of chemotherapy in pediatric Hodgkin lymphoma. Haematologica 55.44 22 Germline lymphoma-predisposing variants: impact on age of cancer diagnosis and survival in pediatric patients. Haematologica 51.12 23 Excess mortality convergence after paediatric allogeneic transplantation: a caveat for the right to be forgotten. Comment on: "Decreasing excess mortality after allogeneic stem cell transplantation for acute leukemia". Haematologica 49.5 24 EARLY DISCONTINUATION OF ANTIBIOTICS IN PEDIATRIC PATIENTS WITH LOW- AND HIGH-RISK FEBRILE NEUTROPENIA: A SINGLE-CENTRE EXPERIENCE. Journal of the Pediatric Infectious Diseases Society 68.4 25 Comment on "How I Approach Anxiety in Children and Teens with Cancer". Pediatric blood & cancer 47.5 26 Progressive Tracheal Injury Following Tumor Regression in a Child With T-Cell Lymphoblastic Lymphoma. Pediatric blood & cancer 28.5 27 Very Late Relapse of Acute Myeloid Leukemia With a Rare HNRNPH1::MLLT10 Fusion Following a Pediatric Myeloid Neoplasm: A Successful Venetoclax-Azacitidine Bridge to Hematopoietic Stem Cell Transplantation. Pediatric blood & cancer 49.12 28 Interventions to Reduce Financial Toxicity of Childhood, Adolescent, and Young Adult Cancer Survivors: A Scoping Review. Pediatric blood & cancer 61.32 29 ENCERT: A Multisite Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide, and Etoposide in Relapsed T-Cell Lymphoblastic Leukemia/Lymphoma. Pediatric blood & cancer 87.42 30 Advanced Radiotherapy Across a Multi-Geography Referral Network for Children With Ewing Sarcoma and Rhabdomyosarcoma: Treatment Delivery and Early Outcomes-A Single-Centre Experience. Pediatric blood & cancer 72.88 31 Genomic Characterization of ETV6::RUNX1-Positive Childhood B-ALL in a Chinese Cohort: Novel Fusion Partners, Co-Occurring Mutations, and Risk-Stratifying Biomarkers. Pediatric blood & cancer 59.75 32 Diagnostic Yield of Brain MRI in Pediatric Short Stature: Hypothalamic-Pituitary Lesions and Incidental Findings in Real-World Practice. Clinical endocrinology 67.3
PATIENT-FRIENDLY SUMMARY

What Are the Complications, Reconstruction Survival, and Functional Outcomes of Modular Prosthesis and Allograft-prosthesis Composite for Proximal Femur Reconstruction in Children With Primary Bone Tumors?

For education only—not personal medical advice.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic